QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further ...

There is no dearth of treatments that claim to hold back ageing. No magic pill exists that is proven to work - but we do know of some that might. It is an ancient dream of humankind - the dream of ...

A new review article published in Genes & Diseases explores the intricate relationship between non-coding RNAs and oxidative stress in cancer progression shedding new light on the mechanisms that ...

A recently published study by the the Western Ontario Registry for Early OA (WOREO) Knee Study team suggests that while synovitis increases in OA, the exhaustion and dysfunction of immune-regulatory ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on ...

Senate File 360 would prohibit health care providers from administering gene-based vaccines, with penalties of a misdemeanor charge and a fine of $500 for each violation.

Automation and artificial intelligence (AI) will be key to a new effort to manufacture millions of RNA vaccines in Africa.

Promega has filed a patent infringement lawsuit against Aobious to halt unauthorized sales of key components of NanoLuc® ...

Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...